A Gram Research analysis of lab-grown brain organoids found that those with a 15q13.3 genetic deletion showed different developmental patterns compared to normal organoids, with a significant difference in response to prolonged vitamin A treatment (P = 0.0083). However, researchers could not confirm this was due to specific vitamin A signaling problems, as the difference appeared to reflect overall developmental timing rather than a vitamin A-specific effect. This early-stage laboratory research does not yet have direct implications for treating people with this rare deletion.
Scientists grew tiny brain-like structures in the lab from cells of people with a rare genetic deletion called 15q13.3. They compared how these mini-brains developed compared to normal ones, looking specifically at whether a vitamin A-related process called retinoic acid signaling worked differently. The study found that the deletion organoids did develop along a different timeline, but the researchers couldn’t confirm whether this was specifically due to problems with vitamin A signaling or just general differences in how fast the cells matured. This early-stage research helps scientists understand what happens in this rare genetic condition.
Key Statistics
A 2026 exploratory study of lab-grown brain organoids from 3 people with 15q13.3 deletion and 17 controls found a significant developmental difference in response to prolonged vitamin A treatment (P = 0.0083), though this appeared related to general maturation rather than vitamin A signaling specifically.
Researchers examining 20 cortical organoid donors (3 with 15q13.3 deletion, 17 controls) found that a broad vitamin A-associated differentiation score showed a negative slope difference between groups (false-discovery rate = 0.0206), but sensitivity analyses did not identify a vitamin A-specific component.
In a 2026 analysis of developmental gene expression in brain organoids, early vitamin A exposure signatures were not significantly different between 15q13.3 deletion and control samples, suggesting vitamin A’s role in this deletion may be indirect.
The Quick Take
- What they studied: Whether tiny brain structures grown from cells with a 15q13.3 deletion develop differently than normal brain structures, particularly in how they respond to vitamin A-related signals
- Who participated: Lab-grown brain organoids (miniature brain-like structures) created from cells of 3 people with the 15q13.3 deletion and 17 people without the deletion
- Key finding: The deletion organoids showed different developmental patterns compared to controls, with a significant difference in how they responded to prolonged vitamin A treatment (P = 0.0083), though this may reflect general maturation differences rather than specific vitamin A signaling problems
- What it means for you: This is very early research using lab-grown tissue, not human studies. It suggests the 15q13.3 deletion may affect how brain cells develop, but much more research is needed before any treatments could be developed. This finding does not yet have direct implications for people with this deletion.
The Research Details
Researchers created tiny brain structures called organoids from cells of people with and without the 15q13.3 deletion. These organoids are grown in laboratory dishes and mimic some aspects of how the brain develops. The scientists tracked how genes were turned on and off over time in these organoids, comparing the deletion group to the control group. They specifically looked for patterns related to vitamin A signaling, which is important for brain development. The study examined data from 3 deletion donors and 17 control donors, focusing on donors rather than individual samples as their main unit of analysis.
Understanding how genetic deletions affect brain development at the cellular level is important for eventually developing treatments. By studying organoids in the lab, scientists can observe developmental processes that would be impossible to study directly in people. This research helps identify which biological processes might be disrupted by the 15q13.3 deletion, which could guide future research into therapies.
This is a small, exploratory study designed to generate ideas for future research rather than prove a specific hypothesis. The researchers were honest about limitations: only 3 people with the deletion were studied (a very small group), the organoids came from different sources which made them somewhat different from each other, and the findings could not be independently confirmed. The study provides useful biological context but should be viewed as a starting point, not a definitive answer.
What the Results Show
The organoids from people with the 15q13.3 deletion showed a different developmental trajectory compared to control organoids when exposed to prolonged vitamin A treatment. This difference was statistically significant (P = 0.0083), meaning it’s unlikely to have occurred by chance. However, when researchers adjusted their analysis to account for how mature the cells had become, the vitamin A-specific effect disappeared. This suggests the difference might be due to overall developmental timing rather than a specific problem with how vitamin A signals work in deletion cells. A broader maturation score (measuring how developed the cells were) showed a strong correlation with the vitamin A treatment response, indicating that developmental stage is the key factor.
Early vitamin A exposure signatures did not show significant differences between deletion and control organoids. The researchers also found that a non-vitamin A maturation score was significant, reinforcing that general developmental maturation, not vitamin A signaling specifically, appears to be the main difference. External analyses and single-cell studies provided additional biological context but did not independently confirm the findings.
This study builds on existing research showing that the 15q13.3 deletion affects brain development, but it is one of the first to examine vitamin A signaling specifically in this context. The findings suggest that if vitamin A is involved in the 15q13.3 deletion phenotype, it may work through general developmental processes rather than through a specific vitamin A signaling pathway. This is consistent with the idea that the deletion affects multiple aspects of brain development.
The study had several important limitations. Only 3 people with the deletion were included, which is a very small sample size and limits how much the findings can be generalized. The organoids came from different sources and were somewhat heterogeneous, meaning they weren’t all identical. The study could not independently validate its findings using a separate dataset. The researchers could not establish whether vitamin A deficiency, altered vitamin A signaling, or vitamin A treatment would actually be relevant to people with this deletion. These limitations mean the results should be viewed as preliminary and hypothesis-generating rather than conclusive.
The Bottom Line
This research does not yet support any clinical recommendations. It is very early-stage laboratory research that has not been tested in people. Anyone with the 15q13.3 deletion should continue following their doctor’s guidance and should not make changes based on this study. Future research is needed to determine whether vitamin A or related treatments might be helpful.
Researchers studying the 15q13.3 deletion and brain development should be aware of these findings as they plan future studies. Families affected by this deletion may find it interesting as background information, but it does not yet have direct clinical implications. This research is not relevant for general population health decisions.
This is basic research using lab-grown tissue. Even if vitamin A-related treatments prove promising in future studies, it would typically take many years of additional research before any treatments could be tested in people. Do not expect clinical applications in the near term.
Frequently Asked Questions
What is the 15q13.3 deletion and why is it important to study?
The 15q13.3 deletion is a rare genetic condition where a small piece of chromosome 15 is missing. This deletion can affect brain development and is associated with developmental delays and seizures. Studying how it affects brain cells helps scientists understand the condition and develop potential treatments.
Can vitamin A treatment help people with 15q13.3 deletion based on this research?
This study does not support vitamin A treatment for 15q13.3 deletion. The research found developmental differences in lab-grown organoids but could not confirm that vitamin A signaling was specifically affected. Much more research in people would be needed before any treatment recommendations.
How reliable are results from organoids compared to studying actual brains?
Organoids are useful for early research because they mimic some aspects of brain development in a controlled setting. However, they are simplified models that don’t capture everything about real brain development. Results from organoids must be confirmed in additional studies before they apply to people.
Why did the vitamin A effect disappear when researchers adjusted for cell maturity?
When researchers accounted for how developed the cells had become, the vitamin A-specific difference was no longer significant. This suggests the organoids’ different response to vitamin A was mainly due to developing at different rates, not from a specific problem with vitamin A signaling itself.
What should families with 15q13.3 deletion do with this information?
This is very early laboratory research that does not yet have clinical applications. Families should continue working with their healthcare providers and genetic counselors. This study does not support any changes to current medical care or suggest new treatment options at this time.
Want to Apply This Research?
- Not applicable. This research does not yet support any specific health tracking or behavioral interventions for users.
- No behavior changes are recommended based on this research. Users should continue following their healthcare provider’s guidance regarding any genetic conditions.
- Users with the 15q13.3 deletion should monitor for updates from their healthcare providers and genetic counselors as new research emerges, but this particular study does not warrant any changes to current monitoring practices.
This research describes early-stage laboratory findings using organoids (lab-grown tissue structures) and does not represent clinical evidence for treating people with 15q13.3 deletion. The study is exploratory and hypothesis-generating, with significant limitations including a very small sample size (3 deletion cases) and inability to independently validate findings. These results do not establish that vitamin A deficiency, altered vitamin A signaling, or vitamin A treatment is relevant to people with this deletion. Anyone with 15q13.3 deletion or a family member affected by this condition should consult with their healthcare provider or genetic counselor before making any health decisions. Do not use this research to guide treatment choices without professional medical guidance.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.